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ABSTRACT  
An APOE- ε4  genotype is the strongest common genetic determinant of Alzheimer’s disease (AD). 
The pleiotropic nature of apolipoprotein E, has made elucidation of the aetiological basis difficult to 
establish which is further complicated by the fact that the penetrance of the APOE- ε4  allele is 
modulated by sex, age, and nutrition.  
A greater metabolic consequence of the APOE- ε4  allele is likely to contribute to the fact that two 
thirds of AD patients are female. A higher tissue status of the marine n-3 fatty acid docosahexaenoic 
acid (DHA), is associated with a lower AD risk. However, APOE- ε4  carriers appear less sensitive to 
the neurocognitive benefits, which may be due to defective blood brain barrier transport of DHA 
exacerbated by ageing and possibly sex. This suggests higher DHA requirements in this large 
population subgroup. This narrative review will consider the influence of sex and DHA in modulating 
APOE- ε4 mediated AD risk 
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1. Introduction  
Dementias, of which Alzheimer’s disease (AD) is the most common, are complex multifactorial 
disorders that manifest progressively over time, with deleterious behaviours and genetic 
predisposition contributing to compromised cognitive function. The apolipoprotein E ε4 allele 
(APOE-ε4) is the strongest prevalent  genetic risk factor for sporadic late-onset Alzheimer’s disease 
(LOAD) with possession of one or two APOE-ε4 conferring respectively 3-4, and 8-12-fold increased 
risk, and reduced age of onset (Davidson et al., 2007; Heffernan et al., 2016). While a significant risk 
factor, possession of an APOE-ε4 does not categorically determine AD outcome (Corder et al., 1993; 
Liu et al., 2013) . Indeed, although APOE-ε4 prevalence within global AD populations varies 
considerably ranging from 41% - 61% (Crean et al., 2011; Farrer et al., 1997; R.M. Corbo, 1999), only 
half of APOE-ε4 homozygotes  develop AD by age 90 years (Henderson et al., 1995). This indicates 
that the penetrance of the E4 allele, it’s influence on the rate of cognitive decline and the likelihood 
of transitioning to MCI and AD, is variable and therefore potentially modifiable (Fenesi et al., 2017; 
Moser and Pike, 2017; Singh et al., 2006; Ward et al., 2012). 
Due to the pleiotropic nature of apolipoprotein E (apoE), possession of the deleterious APOE- ε4  
allele influences multiple biological processes, including inflammation, amyloid beta deposition, 
neurogenesis, synaptic function and lipid metabolism (including cholesterol and docosahexaenoic 
acid (DHA)) (Alata et al., 2015; Holtzman et al., 2012; Huang and Mahley, 2014; Theendakara et al., 
2016). Originally described for its role in lipid transport, in contrast to the systemic circulation, apoE 
is the almost exclusive lipid transporter within the central nervous system (CNS)(Bu, 2012).  
Regular consumption of long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA, eicosapentaenoic 
acid (EPA) and DHA, found in higher concentration in oily fish) is associated with reduced AD risk 
(Barberger-Gateau et al., 2007; Zhang et al., 2016). Current evidence suggests that the cognitive 
responsiveness to DHA intake is lower in APOE- ε4  individuals (Childs et al., 2014; Davis et al., 2017; 
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Furthermore, the pathological impact of APOE- ε4  carrier status appears to be modified by sex, with 
female carriers found to have increased MCI or AD risk between the ages of 55 and 70 years 
compared to their male counterparts (Farrer et al., 1997; Neu et al., 2017), suggesting a possible role 
of menopausal transition.   
Therefore, those with an APOE- ε4  genotype, particularly post-menopausal females, are a large ‘at-
risk’ population group who should be targeted for preventive intervention, such as LC n-3 PUFA 
supplementation. Strategies capable of delaying disease onset by as little as two years would have 
profound implications on current disease burden (Brookmeyer et al., 1998). Recent predictive UK 
models suggest that achieving a two or five year delay would result in a respective 19% or 33% 
reduction in the predicted AD prevalence by 2050 (Lewis F, 2014), and alleviate the social and 
economic pressures associated with this debilitating disease.  
This review will consolidate the current evidence of the interactive role of APOE genotype, DHA 
status and sex in the development of AD, highlighting research gaps and directions for future 
investigation. 
 
2. Contribution of APOE genotype to AD risk  
The human APOE gene, located on chromosome 19, has three common alleles, ε2, ε3 and ε4. 
Relative to the most common isoform APOE- ε3 (allele frequency 78%) the rarer APOE- ε2 (allele 
frequency 7%) is considered protective (Liu et al., 2013), whilst the APOE- ε4  isoform (allele 
frequency 14%) predisposes to AD. Systematic reviews and meta-analyses consistently describe 
strong APOE- ε4 -AD associations. For example using the AlzGene database, increased odds ratios 
(ORs) for both heterozygous (OR: 2.8, 95% CI: 2.3–3.5)  and homozygotes (OR: 11.8, 95% CI: 7.0–
19.8) APOE- ε4  relative to ‘neutral’ APOE- ε3 homozygotes were reported (Bertram et al., 2007). The 
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relative to the global frequency estimated at 14% (in people <65 years of age) (D M Hallman, 1991; 
Eisenberg et al., 2010; Ward et al., 2012). Such associations are also apparent in mild cognitive 
impairment (MCI). APOE- ε4  carriers are 3.0-3.7 times more likely to develop MCI compared to all 
other groups (Viticchi et al., 2017) and APOE- ε4  MCI are more likely to convert to a more severe 
state of MCI (mMCI) or AD (Scarabino et al., 2016). APOE- ε4  has been associated with hippocampal, 
amygdala and medial-temporal lobe atrophy (Lupton et al., 2016; Manning et al., 2014), which 
underlies the greater development and conversion rates in this genotype subgroup.  
A consensus is developing that the impact of the APOE- ε4  allele on AD risk diminishes upon 
reaching extreme ages (>90 years) (Corrada et al., 2013),(Valerio et al., 2014) which is reflected by 
the reduced allele frequency within the AD population (Corrada et al., 2013). Such a trend is 
unexpected given that the APOE- ε4 variant is attributed to an increased risk and reduced age of 
onset. The phenomenon has been attributed to the survivor effect and the fact that these 
individuals have other phenotypic attributes which offer protection with many APOE- ε4 carriers 
reaching extreme ages with normal cognition (Corder et al., 1994; Rebeck et al., 1994). The study of 
such indiviudals is likely to provide valuable insights into strategies to mitagte the effect of genotype 
at younger ages. 
 
3. Impact of sex on AD risk  
3.1 Sex disparity in MCI and AD incidence 
Sex influences dementia risk and prevalence (Podcasy and Epperson, 2016). Above age 65 years 
there are approximately twice as many female AD cases (Seshadri et al., 1997). Although the higher 
prevalence has been attributed to longevity, the global five year longer lifespan in females (2017) 
can arguably only partially explain this phenomenon (Snyder et al., 2016). The reasons for this are 
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the loss, after menopause, of the neuroprotective effect of estrogens, important in maintaining 
synaptic plasticity, neurotransmission and blood brain barrier (BBB) integrity (Karp et al., 2017; 
Maggioli et al., 2016; McEwen and Milner, 2017). However, current clinical trials using hormone 
replacement therapy have failed to yield any promising results (Marjoribanks et al., 2017). 
Interestingly, analysis of murine hippocampal expression profiles reveals that key AD associated 
genes affecting energy and amyloid deposition are considerably altered prematurely in females, 
predisposing them to the development of the disease (Zhao et al., 2016).  
A greater penetrance of an APOE- ε4  genotype in females, first reported in the early 90s (Payami et 
al., 1994), could also explain these higher AD rates. A subsequent meta-analysis, found that carrying 
one APOE- ε4  allele had a substantial effect on AD risk in females relative to non-carriers (OR: ≈4 at 
65 years), whilst their male counterparts remained at similar risk (OR: ≈1 at 65 years) (Farrer et al., 
1997) (Table 1 and Figure 1). This somewhat ‘understudied’ association, has been reiterated over the 
years (Bretsky et al., 1999; Gao et al., 1998; Holland et al., 2013; Xing et al., 2015), including work 
conducted by Altmann and colleagues who observed that the conversion of healthy controls to 
MCI/AD in APOE- ε4  carriers was stronger in women (HR: Female = 1.81 Male = 1.27), with female 
APOE- ε3/ ε4 more likely converting from MCI to AD (HR: Female = 2.17 and Male = 1.51 versus 
APOE- ε 3/ ε3) (Figure 1) (Altmann et al., 2014). A contemporary meta-analysis from the Global 
Alzheimer’s Association Interactive Network (n=27 studies, 58,000 participants) has offered novel 
insight into this interaction. Despite no overall significant difference between men and women on 
APOE- ε4 -AD in 55-85 year olds, the influence of sex emerged as being age-dependent. APOE- ε4  
females were at higher risk of MCI at ages 55-70 years and of AD at 65-75 years relative to APOE- ε4  
males, with the sexual dimorphism disappearing after 75 years (Neu et al., 2017). This indicates that 
a higher susceptibility to the APOE- ε4  allele in females is most evident in the decade(s) following 
menopause. As with the overall reduction of penetrance of genotype on AD risk at older ages 
described above, a loss of effect of sex may be due to selective survival of those females less 













7 | P a g e  
 
 
3.2 Female sex exacerbates the neurocognitive impact of an APOE- ε4  genotype  
Limited human cognitive and biomarker data support the sexual dimorphism evident in 
epidemiological (incident disease) studies, indicating earlier onset and more extensive pathology in 
female APOE- ε4  carriers. Differences in cerebrospinal fluid (CSF) tau and Aβ42 load (Altmann et al., 
2014; Li et al., 2017) along with aberrant Aβ/secretase profiles in autopsy samples (Nyarko et al., 
2018)  and  brain hypometabolism and cortical thinning (Sampedro et al., 2015) have been observed 
between female and male APOE- ε4 . Fleisher et al. observed reduced hippocampal volume and 
memory performance in female relative to male APOE- ε4  carriers, in whom significant pathological 
changes only occurred when in possession of two APOE- ε4  alleles (Fleisher et al., 2005). Analysis of 
>5000 brain samples of varying ages found that women carrying the APOE- ε4  gene had more 
extensive neurofibrillary tangles and senile plaques, with onset of pathology beginning considerably 
earlier (Corder E. H., 2004). Neuroprotective immune cell (Aβ-specific CD4+ T cell) decline was found 
to occur 10-15 years earlier in female carriers compared to that of male carriers (Begum et al., 
2014). Finally, levels of brain-derived neurotrophic factor (BDNF), an important modulator of neuron 
survival and growth in areas associated with memory, have been found to be significantly reduced in 
APOE- ε4  females relative to age matched APOE- ε4  males, and to correlate to poorer MMSE scores 
(Alvarez et al., 2014).  
Rodent studies also highlight such a trend. It is widely accepted that female APOE- ε4  mice present a 
more extreme phenotype (Raber et al., 1998; Rodriguez et al., 2013), with greater cognitive decline 
evident from their poorer performance on a battery of behavioural tests (Bour et al., 2008; 
Grootendorst et al., 2005; Heneka et al., 2015; Rodriguez et al., 2013), and a greater extent of 
neurodegeneration (Koutseff et al., 2014; Rijpma et al., 2013). For example Bour et al., 
demonstrated that 15-month female APOE- ε4  targeted replacement (TR) mice had significantly 
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2008). This is consistent with findings of Rijpma et al. who found middle aged APOE- ε4 -TRfemale 
mice had decreased presynaptic density within the hippocampus, which was not found in APOE- ε4  
males (Rijpma et al., 2013). Wang et al, reported learning and memory impairment, occurring at a 
much younger age in APOE-ε4 /3xTg (sporadic and familial genes) females, which coincided with 
higher Aβ proteins and β-site amyloid precursor protein cleavage enzyme (BACE1) when compared 
to female nonTg, female 3xTg and male APOE-ε4 /3xTg mice(Wang et al., 2016).   
To the best of our knowledge, the impact of sex on APOE genotype- DHA associations is currently 
completely unknown, but likely to be important, given the known role of sex on liver and systemic 
fatty acid synthesis and metabolism, and the differential impact of APOE- ε4 on brain DHA uptake 
and status (addressed below).  
 
3.2.1 Menopause and sex hormone dysregulation as a potential explanation for sex- APOE- ε4  
associations in AD  
The process of menopause may offer an explanation for the greater AD susceptibility exhibited by 
females (Li et al., 2014). It may also help to explain why females appear to be predisposed to the 
effects of APOE- ε4  carrier status (Mosconi et al., 2017; Moser and Pike, 2016; Yun et al., 2007; 
Zokaei et al., 2017). Earlier onset of menopause correlates with poorer cognition later in life (Ryan et 
al., 2014). The abrupt hormone dysregulation caused by the menopausal process, is likely to have 
significant implications on brain processes and cognition with the neuroprotective importance of 
oestrogens and progesterone well documented in the literature (reviewed extensively (Depypere et 
al., 2016; Vest and Pike, 2013)). A recent study using multimodal brain-imaging techniques 
highlighted the impact of menopause in AD development, with indicators of AD, such as hypo-
metabolism, increased Aβ deposition and reduced grey and white matter brain volumes all evident 
to a greater extent as a result of menopause (menopause > perimenopause > no menopause) even 
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exacerbated menopausal Aβ deposition relative to other groups, which indicates an APOE- ε4 -
menopause interaction (Mosconi et al., 2017). 
One would speculate that re-establishing the hormone profile altered in menopause would 
ameliorate these deleterious effects. However, inconsistent effects of hormone replacement 
therapy have been reported in both the general population and APOE- ε4  carriers. These 
discrepancies are likely attributable to the heterogeneity in the initiation, treatment period, dose 
and combination of hormones used. Although currently inconclusive and sparce, the limited 
research available, addressing the impact of APOE genotype on the efficacy of hormone theapy 
appears to complicate this paradigm further with reports of both improvements (Jacobs et al., 2013; 
Kunzler et al., 2014; Yun et al., 2007), and no effect (Kang and Grodstein, 2012; Kunzler et al., 2014; 
Yaffe et al., 2000), in relation to cognition for carriers of APOE- ε4. Although oestrogen and 
activation of their receptors are known to alter APOE expression (Corbo et al., 2006; Wang et al., 
2006), the molecular aetiology of possible APOE genotype-hormone-cognition interactions is not 
known.  
Further research is needed to establish the benefits of hormone intervention during menopause and 
whether the effects are APOE genotype dependent, thereby warranting stratified approaches. 
 
4. DHA: a dietary component with implications in AD  
DHA, is a 22-carboxylic fatty acid consisting of 6 C=C double bonds (22:6n-3). An important 
constituent of the CNS, DHA can be synthesised from simpler precursors or obtained directly from 
the diet, predominantly from marine sources such as oily fish.  
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DHA is particularly concentrated in the brain (Arterburn et al., 2006), and accounts for 15% of the 
total fatty acids in the cerebral cortex. This dwarfs the levels found in the peripheral tissue such as 
the heart and liver, where DHA contributes about 2% (Arterburn et al., 2006). DHA is distinctly 
associated with the grey matter (Bradbury, 2011), and is highly concentrated within metabolically 
active neuronal regions (Bradbury, 2011; Crawford et al., 2013), including synaptic membranes, 
synaptic vesicles and mitochondria (Neuringer et al., 1988). DHA concentration varies across 
phospholipid species, and is abundant within phosphatidylserine and phosphatidylethanolamine, 
where DHA makes up around one third the total fatty acid composition (Lauritzen et al., 2001; 
Neuringer et al., 1988).  
Synthesis of DHA in the brain occurs to a very limited extent (Igarashi et al., 2007), failing to increase 
even in times of n-3 PUFA deprivation (Igarashi et al., 2007). Brain DHA is supplied from the systemic 
circulation, with the DHA provided from the diet or synthesised mainly in the liver from its shorter 
chain precursor a-linoleic acid (ALA) (Domenichiello et al., 2015), through the actions of desaturase 
and elongase enzymes (Igarashi et al., 2006).  
Upon entry into the brain, DHA is activated and esterified to the cell membrane phospholipids at the 
sn2 position, where it is believed to have a range of beneficial structural and functional roles. The 
unique highly polyunsaturated, kinked structure of DHA increases membrane fluidity, regulating the 
properties of the membrane and therefore affecting a range of properties including membrane 
protein function. DHA is also associated with promoting antioxidant processes, and altering gene 
expression profiles (Hashimoto et al., 2016). This occurs through the release of DHA from the 
membrane under the action of phospholipase A2.  Although most is quickly re-esterified and 
conserved, release from the membrane allows DHA to partake in multiple signalling and regulatory 
processes, the most documented of which is DHA’s role in neuroinflammation. The metabolism of 
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transforms DHA into a plethora of bioactive lipid metabolites such as resolvins, protectins and 
maresins (Kuda, 2017), which are renowned for their anti-inflammatory properties.  
 
4.2 Does DHA intake and status affect Dementia risk?  
Prospective epidemiological studies, summarised by a number of meta-analyses, indicate that a 
higher consumption of fish and oily fish, the almost exclusive dietary source of LC n-3 PUFA is 
associated with reduced dementia and AD risk (Table 2) (Barberger-Gateau et al., 2002; Barberger-
Gateau et al., 2007; Kalmijn et al., 1997; Morris et al., 2003; Zhang et al., 2016). To put this beneficial 
effect into perspective, the meta-analyses conducted by Wu and colleagues reported an 11% risk 
reduction in AD with each 100g increment of fish consumption per week (Wu et al., 2015), with 
Zhang et al. observing that a 0.1g increment in DHA per day was associated with 14% and 37% lower 
risks of dementia and AD respectively (Zhang et al., 2016).    
Higher circulating DHA concentrations have been associated with improved cognition and reduced 
dementia and AD risk. Conquer et al. reported that AD patients have lower plasma DHA levels, in the 
total phospholipid, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) fractions (Conquer 
et al., 2000). This was reiterated in the Framingham study where those in the top quartile of plasma 
PC-DHA had a 47% lower dementia risk relative to the bottom quartile (Schaefer et al., 2006), which 
is consistent with the Rancho Bernado study (Lopez et al., 2011). Interestingly those in the 
Framingham study in the lowest RBC DHA quartile also had lower total brain volume and performed 
poorer on a range of cognitive tests including visual memory, executive function and abstract 
thinking tasks (Tan et al., 2012). Further to this Yassine et al reported an association between serum 
DHA and cerebral amyloidosis and brain volumes (particularly those areas affected by AD) (Yassine 
et al., 2016a). Although not fully consistent, post mortem brain analysis also indicate that DHA levels 
are reduced in AD (Fraser et al., 2010; Söderberg et al., 1991). This beneficial assosiation appears to 
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found participants within the lowest serum DHA quartile to have significantly more cerebral 
amyloidosis (Yassine et al., 2016a), However it appears there is little research examining  the effects 
of DHA within the oldest old (85 + years), an area which warrents investigation. 
A high oily fish and DHA consumption is associated with a higher socio-economic status, with such 
subgroups typically being more educated, engaging in higher physical activity, having lower 
prevalence of smoking and higher consumption of plant based foods, all of which have been shown 
to be neuroprotective. Although data analysis approaches correct for the impact of such co-variates, 
not all analyses are fully comprehensive and there may be other associated behavioural attributes 
which have not been considered. Therefore a proportion of the reported benefits of fish/DHA may in 
certain instances be attributable to the residual confounding effect of these associated factors.  
Although collectively the observational data demonstrate that a high, habitual oily fish and DHA 
intake, and DHA status, are associated with a reduction in AD risk, these findings have not been 
consistently supported by randomised controlled trials (RCTs). RCTs have yielded conflicting results; 
some displaying promise (Lee et al., 2013; Stonehouse et al., 2013; Vedin et al., 2008; Yurko-Mauro 
et al., 2010), whilst others have failed to establish any beneficial effects (Joseph F. Quinn, 2010; 
Phillips et al., 2015; Quinn et al., 2010). Stonehouse et al. observed improved memory and reaction 
time in healthy young adults supplemented with 1.16g DHA for 6 months (Stonehouse et al., 2013). 
In the Alzheimer’s Disease Cooperative Study (ADCS) which recruited those with mild to moderate 
AD, no cognitive benefits were evident following the consumption of 2g DHA daily for 18m (Quinn et 
al., 2010). RCTs to date have been predominately in individuals with existing MCI or AD who will 
have already experienced significant neuronal loss, thereby potentially missing the ‘window’ of 
preventive and therapeutic intervention. It is increasingly understood that the initial neuropathology 
which ultimately manifests in clinical AD, typically occurs some 20-30 years before any noticeable 
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DHA, should target pre-clinical at-risk and prodromal groups, in order to maximise the individual and 
population benefits. 
Apparent inconsistencies in RCT findings are also likely to be due to other heterogeneous elements 
of experimental design, such as DHA dose, habitual DHA status of trial participants (with likely 
greater benefit in those with a low baseline status, typical of western populations (Stonehouse et al., 
2013)) and length of intervention. Brain DHA half-life is estimated to be up to 2.5 years, with 
mechanisms in place to conserve DHA in times of deprivation (Rao et al., 2007; Rapoport et al., 2007; 
Umhau et al., 2009). Many RCT are therefore too short to result in appreciable differences in brain 
DHA and associated neurocognitive benefits. 
  
4.3 Pre-clinical and in vitro studies suggest DHA benefit  
Interestingly, a number of cellular and pre-clinical studies demonstrate that DHA can ameliorate 
deleterious biological processes associated with AD, including some of those linked to an APOE 
genotype, as described above. Supplementing AD mouse models with a 0.6% DHA diet significantly 
reduced Aβ plaque formation (Lim et al., 2005; Teng et al., 2015) and affected amyloid precursor 
protein processing in Tg2576 mice  (Lim et al., 2005). In addition, DHA was also observed to 
modulate Aβ aggregation by stabilising oligomers in APP/PS1 mice (Teng et al., 2015). This is 
consistent with in vitro findings (Hashimoto et al., 2009). Similarly, AD rodent models have revealed 
that DHA supplementation reduces aberrant phosphorylation of tau resulting in improved cognitive 
performance in 3xTg-AD mice (Arsenault et al., 2011). With DHA known to modulate cellular 
inflammation by multiple mechanisms (Calder, 2017), it is of no surprise that DHA supplementation 
reduces neuroinflammation. Combined EPA and DHA supplementation prevented cytokine 
expression and alterations in astrocyte morphology in aged wild type C57BL/6 mice (Labrousse VF, 
2012). Hopperton and Thomas reported an effect of DHA supplementation on microglia activation   
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model. It should be noted however that such rodent studies tend to employ large doses of DHA 
(human equivalent of ≈2-4g) (Arsenault et al., 2011; Chouinard-Watkins et al., 2017) for extended 
periods of time (in relation to a mouse lifespan ≈ 2 years) (4-8 months) (Arsenault et al., 2011; Lim et 
al., 2005; Teng et al., 2015). These strategies are utilised in the attempt to maximise the chance of 
observing cognitive benefit, therefore achieving such studies in humans may prove difficult or 
unfeasible.  Despite their importance in the research of complex disease, current rodent models of 
AD have recognised limitations (McGowan et al., 2006), associated with dissimilar human-to-mouse 
lifespan and environmental conditions. As a result pathological protein profiles may differ chemically 
and morphologically, and human AD pathology is not fully recapitulated (Richardson and Burns, 
2002). Such inconsistencies in regards to plaque pathology may produce ‘effect sizes’ in mouse 
models which cannot be reached in humans, which need to be appreciated when interpreting 
rodent data. In addition a wide range of rodent AD models exist, each with unique ageing profiles 
and pathological progressions, strengths and limitations These need to taken into account when 
collectively interpreting the results from rodent experimentation (Tai et al., 2011).  
 
5. DHA availability and transport in the brain 
5.1 Transport to the Brain  
Effective circulatory transport and BBB uptake of DHA, is crucial for maintaining brain supply. DHA 
derived from the diet, synthesised in the liver or released from reserves in adipose tissue is packaged 
into various plasma pools for transportation (Lefkowitz et al., 2005), either in lipoproteins (esterified 
as triglycerides (TAG), diacylglycerol, phospholipids (PL) or cholesteryl esters or bound to albumin as 
non-esterified DHA or esterified to lysophosphatidylcholine (LPC) (Lagarde et al., 2001). The 
importance of each pool in supplying brain DHA is still widely debated; however, current evidence 
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DHA pool being quantitatively the major physiological pool despite LPC-DHA being preferentially 
incorporated after a single dose (Chen et al., 2015). The observation of adequate brain DHA status in 
LDL and VLDL receptor knockouts, indicates that direct lipoprotein uptake of DHA is not a significant 
source (Chen et al., 2008; Rahman et al., 2010). A more complete understanding of the ability of 
DHA pools and dietary sources to target the brain is of high therapeutic relevance, potentially 
leading to more effective use of DHA intervention to support healthy brain ageing.   
 
5.1.1 DHA transport across the blood brain barrier 
The movement of DHA across the BBB may be passive, transporter-mediated or a combination of 
both processes (Figure 2). Rodent studies and model membranes have demonstrated that un-
esterified DHA can freely cross the BBB via simple diffusion (yellow arrow) (Ouellet et al., 2009), 
supporting the notion, that diffusion alone is adequate. Cluster of differentiation 36 (CD36) was 
previously believed to be a transporter of un-esterified DHA, however CD36 knockout mice do not 
display DHA deficits in the brain (3 – Red arrow) (Song et al., 2010). Similarly, the importance of 
lipoprotein mediated DHA uptake has been questioned; with LRP receptor knockout mice exhibiting 
normal DHA brain levels and supply (4 – Red arrow) (Chen et al., 2008; Rahman et al., 2010). Instead, 
it is now proposed that under the action of lipoprotein lipase at the BBB, lipoprotein DHA is released 
as free fatty acid enabling simple diffusion across the BBB (5) (Chen and Subbaiah, 2013; Sovic et al., 
2005).  
In contrast, major facilitator superfamily domain-containing protein 2 (Mfsd2a) provides evidence 
that transporter mediated routes are indeed necessary for sufficient DHA transport to the brain. 
Expressed in the BBB endothelium, Mfsd2a appears to be an integral part of DHA transport across 
the BBB and specifically transports LPC esterified DHA (6 – green arrow) (Nguyen et al., 2014). 
Mfsd2a’s importance is evident from mice lacking the transporter. These knockout mice exhibit 
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neurodegeneration, which manifests as significant cognitive impairment (Nguyen et al., 2014; Wong 
et al., 2016).  
In addition to Mfsd2a, various fatty acid binding proteins (FABP) have been implicated in DHA uptake 
and retention. Pan et al. discovered a role for the carrier protein FABP5, which is the most expressed 
FABP at the BBB (Lee et al., 2015). Confirming that FABP5 binds un-esterified DHA with high affinity, 
the group optimised an in situ trans-cardiac perfusion technique and deduced that transport of 
14
C-
DHA, was reduced by 36% in FABP5 deficient mice (Pan et al., 2015). They recently continued this 
line of research, describing how FABP5 knockout mice have a 14% reduction in cortical DHA levels. 
Loss of FABP5 and subsequent reduction in DHA transport translates to significant cognitive deficits, 
illustrating the importance of both FABP5 and DHA in cognitive health (Pan et al., 2016). 
Interestingly endothelial cell uptake of DHA was significantly impaired (48%) whilst cell transport 
was unaffected (Pan et al., 2016), providing evidence that FABP5 influences uptake, and not 
endothelial cell transport, as originally thought (7 – Green arrow and 8 – Red arrow).  Finally, 
evidence has recently emerged that supports a role for fatty acid transport protein 1 (FATP1) in DHA 
supply to the brain (Ochiai et al., 2016). FATP1 appears to be a basal membrane transporter with 
initial cell studies suggesting it contributes to DHA transport across the BBB (9 – Green Arrow) 
(Ochiai et al., 2016). However, in vivo follow up experimentation, is required to confirm these initial 
findings.  
In summary, although DHA has been observed to cross the BBB via simple diffusion, there appears to 
be protein mediated processers in place to ensure an adequate supply of this essential molecule, as 
evidenced by Mfsd2a and FABP5 knockout rodent model data. Further characterisation of these 
transporters in aged mice is required to confirm their importance in adult, non-developmental 
related DHA brain transport. Overcoming DHA transport deficits may enhance DHA supply to the 
brain, subsequently improving cognitive health. Potential methods to achieve this include: supplying 
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increasing overall blood DHA status. These methods could be utilised to compensate for the reduced 
delivery efficiency associated with BBB transport deficits e.g. associated with ageing (Graf et al., 
2010) or APOE genotype.  
 
5.2 The influence of APOE genotype on DHA metabolism and status  
Human epidemiological evidence along with RCT data indicate that APOE- ε4 carriers are less 
responsive to the neuroprotective benefits of higher DHA intakes (Huang et al., 2005; Quinn et al., 
2010; Yassine et al., 2017a). Such findings are in agreement  with recent results demonstrating that 
APOE- ε4 TR mice have significantly lower brain DHA concentrations (9% reduction in cortex 
compared to APOE- ε2) (Vandal et al., 2014), therefore indicating impaired DHA transport and/or 
metabolism associated with an APOE- ε4  genotype. Uptake of DHA into the brain has been shown to 
be significantly reduced in APOE- ε4 TR mice and to progressively decline with age (Vandal et al., 
2014), which may be suggestive of BBB transport impairment. This potential transport impairment in 
APOE- ε4  rodents is consistent with findings from the ADCS trial in humans where lower DHA levels 
in the cerebrospinal fluid in APOE- ε4  carriers following DHA supplementation was observed 
(Yassine et al., 2016b). The molecular aetiology of the proposed reduced BBB transport of DHA in 
APOE- ε4, and in particular any effect on the protein mediated transport mechanisms described 
above, is currently unknown.  
 A recently conducted PET study in humans, exploring the incorporation of 
11
C-DHA surprisingly 
reported that young APOE- ε4  carriers have increased DHA brain delivery and incorporation rates 
(Yassine et al., 2017b). Although these findings need to be confirmed in a larger study, this apparent 
increase, contradicts the suggested APOE- ε4 transport deficits. This may represent a compensatory 
mechanism to overcome DHA loss via altered brain metabolism. The progression to further 
transport/metabolism deficits observed in aged APOE- ε4 carriers may overwhelm this 
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carriers to AD. Further investigation is needed to fully establish the effect of APOE- ε4 on DHA 
transport and brain delivery and metabolism and how they are affected by age.  
An altered systemic DHA metabolism, associated with lower overall DHA availability in APOE- ε4 
carriers may also underlie a lower brain DHA status. Chouinard-Watkins et al, observed (using 
radiolabelled
 13
C DHA) a reduced DHA plasma incorporation (31% less), and significantly increased 
DHA β-oxidation (80%) in elderly APOE- ε4  carriers (Chouinard-Watkins et al., 2013) relative to 
APOE- ε4  non-carriers. The greater hepatic uptake and β-oxidation of DHA potentially explains the 
lower plasma response observed in APOE- ε4 carriers with high-BMI (Chouinard-Watkins et al., 
2015). Altered DHA metabolism is apparent in the liver of APOE- ε4 TR  mice, which express APOE 
under m-APOE promoter producing a physiologically relevant APOE model (Tai et al., 2011), in these 
mice PUFA homeostasis is significantly dysregulated, potentially as a result of altered fatty acid 
transporter expression, specifically FABP1 (Chouinard-Watkins et al., 2016). Interestingly 
supplementation with a relatively large dose (3g/day) of DHA restored these deficits observed in the 
liver (Chouinard-Watkins et al., 2016). In light of this, supplementation with larger doses of DHA (up 
to3 g/day) in APOE- ε4  carriers may present a plausible route to overcome the transport and 
metabolism deficits associated with APOE- ε4  (Chouinard-Watkins et al., 2017). Chouinard-Watkins 
and colleagues showed such supplementation prevented memory decline in APOE- ε4 rodent model 
with APOE- ε4  TR mice performing similarly to both APOE- ε3 TR mice fed a normal diet and the diet 
highly enriched with DHA (Chouinard-Watkins et al., 2017; Yassine et al., 2017a). Given the apparent 
deficits in DHA transport and metabolism in those with an APOE- ε4, alternative intervention 
strategies should also be considered.    
To our knowledge, the impact of sex on DHA BBB transport and its interaction with APOE genotype is 
currently completely unknown. It is proposed as a high priority research area to provide insight into 
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6. Conclusion  
The implications of the APOE- ε4 genotype in cognition and AD risk are far-reaching and complex, 
detrimentally influencing a range of AD mechanisms from Aβ deposition to DHA metabolism. This 
makes the process of developing a mitigating intervention challenging. The extent of APOE- ε4’s 
influence appears to be modulated to some extent by a triad of factors namely sex, age and DHA 
status. Targeted nutrition strategies may overcome the negative influence of these factors, 
attenuating genetic vulnerability and ‘tipping the balance’ in favour of AD prevention, particularly if 
such an intervention is implemented early in the disease process. From current evidence, advocating 
the consumption of oily fish and DHA appears a robust approach to reduce AD risk and in APOE- ε4 
carrier’s higher doses may be warranted to achieve the benefit associated with non-carriers, due to 
impairment in transport and metabolism. This may also be true for the elderly who display an age 
dependant transport deficits, and females where the effects of the APOE- ε4 genotype are 
exacerbated.  
Characterisation of the impact of sex and menopausal status on, brain DHA uptake and metabolism 
and responsiveness to DHA intervention, independent of, and according to APOE genotype status 
are identified as research priority area. Dose-response studies in sex by APOE genotype groups are 
needed to identify effective DHA intake doses and develop stratified nutrition intervention 
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9. Figures  
Figure 1: The impact of sex on Mild cognitive impairment (MCI) and Alzheimer’s disease (AD) risk in APOE-Ε4 carriers relative to non-carriers  
From left to right in chronological order: 
 Farrer LA et al. 1997: Odds ratios (OR) for AD risk compared to APOE-Ε3/E3.  
Altmann A. et al., 2014: Report the hazard ratios (HR) for the conversion from (a) healthy controls (HC) to MCI/AD in APOE-Ε4 carriers vs. non-carrier, or (b) MCI to AD 
conversion in APOE-Ε3/E4 vs. APOE-Ε3/E3 
Neu SC et al. 2017: OD for MCI or AD compared to APOE-Ε3/E3. Sex did not influence the sensitivity of APOE-Ε3/E4-AD association in the overall group (aged 55-85 
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Study Study type Basic participant criteria  Follow up length  Outcome (OR/RR/HR) 
Farrer 




40 research groups contributed 
patient data: 
• APOE genotype  
• Sex  
• Age at disease onset  
• Ethnic background  
  
NA • In comparison with APOE- ε3/ ε3, the sexual 
dimorphism in AD risk was 1.5 times greater in 
APOE- ε3/ ε4 individuals (P=.01) 
• See Figure 1 
Altmann 





• Subjects were healthy controls or 
MCI at initial assessment  
• APOE genotype available 
 
Minimum one follow 
up at 12 months or 
later 
• Female APOE- ε4  carriers more likely to develop 
MCI/AD (HR=1.81 women; HR=1.27 men; 
P=0.011)  
• Compared to APOE- ε3/ ε3, APOE- ε3/ ε4 females 
more likely to convert from MCI to AD  (HR=2.17 
women; HR=1.51 men, P=0.022) see figure 1  
• In MCI, APOE- ε4 -sex interaction, significant for 




et al., 2015) 
Cross-sectional study 
N=274 
• AD Neuroimaging Initiative (ADNI) 
database  
• aged 55 to 90 years 
• healthy elderly control individuals 





• Female APOE- ε4  carriers showed brain 
hypometabolism in the temporal cortex P=0.001 
• Female APOE- ε4  carriers showed  cortical 






• Aged ≥65 years 
• Population of Cache County, Utah 
NA • Female sex a risk factor for AD only in those with 
APOE- ε4   (OR=1.58, P=0.02) 
Neu  
(Neu et al., 
2017) 
Meta-Analysis  
N= ≈58 000  
• 27 independent research studies 
• White Participants only mainly 
non-Hispanic  
• Ages 55-85 years excluded all 
patients with a clinical history of, 
or comorbidity 
with any other known 
neurological disease 
Maximum follow up 
10 years 
• No different between sex for APOE- ε4 -AD risk in 
whole group (OR=3.09 men and OR=3.31 women, 
P=0.53)  
• Female E3/E4 had a higher risk of AD between the 
ages of 65 and 75 years (OR=3.14 men and 
OR=4.37, P=0.002) 
• Female  E3/E4 had higher a risk of MCI between 


























Table 1: Key studies supporting the notion of an APOE-Ε4 -sex interaction 
Abbreviations: MCI, Aβ, CSF, MRI, FDG-PET, MRI, BDNF, MMSE – Mild cognitive impairment, Amyloid beta, Cerebrospinal fluid, Magnetic resonance imaging, 










• Aged 55 to 90 years 
• Took part in structural brain MRI 
• MCI at initial assessment 
• Good general health 
NA • Women with 1 or 2 APOE- ε4  alleles were found 
to have significantly reduced hippocampal volume  
•  Men only showed a significant reduction in 
hippocampal volume when carrying 2 APOE- ε4  
alleles. 






Cross-sectional study  
N=362 
• Recruited Healthy, MCI and AD 
patients  
• Excluded all patients with any 
other health conditions  
• not taking various neurological 
medications  
 
NA • Female APOE- ε4  carriers showed lower BDNF 
levels (p<0.01) and MMSE scores (p<0.01) than 
non-APOE- ε4  carriers 
• Males did not  
Li  
(Li et al., 
2017) 
Cross-sectional study  
N=331 
• Aged 21 to 100 
• medically stable 
• no evidence or history of cognitive 
or functional decline 
NA • CSF total tau and p-tau181 had no gender 
differences 
• CSF Aβ42 had age× gender×APOE genotype 
interaction, p=0.047   
• Male APOE- ε4 , average CSF Aβ42 decreased 
gradually with age up to midlife and then levelled 
off. 
• Female APOE- ε4 , average CSF Aβ42 remained 
relatively high through to age 50 and then had a 
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• ≥65 years 
• Dementia free at 
baseline  
• Male and Female  
4 years 1. Weekly consumption of 
fish 
2. Regular n-3 rich oil intake  
1. Reduced AD risk (HR 0.65, 95% CI 0.43 to 0.994) 
2. Reduced all cause dementia risk  (HR 0.60, 95% CI 
0.40 to 0.90) in APOE- ε4  non carriers only  











• 65–94 years 
• Dementia free at 
baseline  




1. Weekly consumption of 
at least one portion of 
fish 
2. Total intake of n-3 PUFA 
1. Reduced AD risk (RR, 0.4; 95% CI 0.2 to 0.9 ) 
2. Reduced AD risk with increasing  n-3 PUFA intake 









• 55-88 years  
• Dementia free at 
baseline 
• Male and Female   
 
 
9.1 years 1. Highest quartile plasma 
PC-DHA levels – equating 
to 3 servings of fish per 
week 
1. Reduced all cause Dementia risk (RR 0.53, 95% CI 









• ≥65 years 
• Dementia free at 
baseline 
• Male and Female  
  
0.1 to 8.4 
years 
1. Fatty fish consumption ≥ 
times per week 
1. Nominal but not significant Reduction in 
dementia risk (HR  0.79; CI 0.53 to 1.20) in APOE- 
ε4  non carriers only  
2. Nominal but not significant Reduction in AD risk 











• ≥55 years 
• Dementia free at 
baseline  
• reported dietary 
information at 
baseline 
• Male and Female   
Average 9.6 
years 
1. High fish intake  
2. N-3 PUFA intake 
1. Those who had a high fish intake (hazard ratio: 
0.95; 95% CI: 0.76, 1.19) and those consuming 
fatty fish (HR: 0.98; 95% CI: 0.77 to 1.24) had a 
similar dementia risk when compared to those 
who typically ate no fish.  
2. Participants in the lowest tertile of long-chain N-3 
intake, had  similar risk of dementia to those in 
the highest tertile (HR: 0.97; 95% CI: 0.77 to 1.21) 
Wu  
(Wu et al., 
Meta-
analysis of 
• Prospective cohort Minimum one 
year follow up 
1. Higher intake of fish 
2. Higher long-chain n-3 
1. 36% reduced AD risk compared with lowest 






















Table 2:  Prospective cohort studies reporting on fish and DHA intakes and dementia risk  
Abbreviations: PUFA, PC-DHA, HR, RR, CI – Polyunsaturated fatty acid, Phosphatidylcholine – docosahexaenoic acid, Hazard ratio, relative risk, confidence interval 
 
Figure 2: DHA - BBB transport mechanisms – Plasma DHA is associated with lipoproteins or albumin depending on esterification status (1). Un-esterified DHA can cross the 
BBB via simple diffusion (2). The uptake of DHA via CD36 (3) and LRP (4) mediated processes are now considered insignificant. Lipoproteins may still contribute as a DHA 
pool under the action of lipoprotein lipase at the BBB (5). Mfsd2a specifically aids the uptake of LPC-DHA into the endothelium (6). FABP5 is implicated in the transport of 







fatty acid intake 
3. Increasing 100g per week 
increment  of fish 
further if using only studies with longer follow up. 
2. No statistically significant association with long-
chain omega-3 fatty acids intake and AD risk 
reduction (RR = 0.89, 95% CI 0.74–1.08). 












N= 181580  
• Prospective cohort 
studies 
2.1-21 ears 1. 1 serving of fish per week  
2. 0.1-g per day increment 
of DHA 
1. Lower dementia (RR: 0.95; 95% CI: 0.90 to 0.99), 
and AD risk (RR: 0.93; 95% CI: 0.90 to 0.95) 
2. Lower  dementia (RR: 0.86; 95% CI  0.76 to 0.96) 













48 | P a g e  
 




















































• The extent of APOE- ε4 ’s influence on Alzheimer’s disease risk may be modulated by sex, 
age and DHA status 
• The effects of the APOE- ε4  genotype are exacerbated in females in the decade(s) following 
menopause 
• Consumption of oily fish, and the n-3 fatty acid DHA, reduces AD risk 
• Higher doses of DHA may be warranted to achieve such benefit in APOE- ε4  carriers, the 
elderly and females 
 
 
